PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

Several drugs approved for a variety of indications have been shown to exhibit antiangiogenic effects. Our study focuses on the PPARγ ligand rosiglitazone, a compound widely used in the treatment of type 2 diabetes. We demonstrate, for the first time to our knowledge, that PPARγ is highly expressed...

Full description

Saved in:

Bibliographic Details
Main Authors:	Panigrahy, Dipak, Singer, Samuel, Shen, Lucy Q., Butterfield, Catherine E., Freedman, Deborah A., Chen, Emy J., Moses, Marsha A., Kilroy, Susan, Duensing, Stefan, Fletcher, Christopher, Fletcher, Jonathan A., Hlatky, Lynn, Hahnfeldt, Philip, Folkman, Judah, Kaipainen, Arja
Format:	Artigo
Language:	Inglês
Published:	American Society for Clinical Investigation 2002
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC151148/ https://ncbi.nlm.nih.gov/pubmed/12370270 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI15634
Tags:	Add Tag No Tags, Be the first to tag this record!

PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

Similar Items